Our Scientific Focus

Apellis is dedicated to improving the lives of individuals living with serious disease driven by complement and supports medical and scientific research that demonstrates the highest level of scientific integrity, inclusion, and curiosity.

  • Hematology
    Paroxysmal nocturnal hemoglobinuria (PNH)

    • Treatment transition strategies and dosing strategies
    • Safety and efficacy in specific subpopulations
    • Biomarkers in clinical management
    • Quality of Life (QoL) and effect on Activities of Daily Living (ADL)
    • Longer-term treatment effects
    • Biomarkers of disease severity
    • Epidemiology of PNH
    • Further characterization and measurement of PNH symptoms (e.g., brain fog)
    • Screening for PNH in risk groups
  • Nephrology
    Immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G)

    • Further disease characterization in patients with either IC-MPGN or C3G
    • Biomarkers of disease severity and disease progression in patients with IC-MPGN/C3G
    • Novel clinical study endpoints of disease severity and disease progression in IC-MPGN/C3G
    • Role of innate immune system in patients with IC-MPGN/C3G
  • Neurology
    Amyotrophic lateral sclerosis (ALS)

    • Biomarkers of disease progression in patients with ALS
    • Biomarkers or prognosis in patients with ALS
    • Novel clinical study endpoints of disease severity and disease progression in patients with ALS
    • Role of innate immune system in patients with ALS
    • Role of immune system in disease progression in ALS
    • Role of innate immune system in neurological disease
  • Ophthalmology
    Geographic Atrophy (GA)

    • Long term (> 5yr) natural history data on geographic atrophy (GA) patients, including impact of progression on patients with low vision
    • Using OCT-A to assess structural changes in the eye during GA progression
    • Development of tests to evaluate and monitor visual function in patients with GA
    • Complement levels in the retina during GA progression
    • Relationship between macular neovascularization (MNV) and development of GA

You are now leaving ApellisMedicalHub.com

You are about to leave ApellisMedicalHub.com to visit a third-party website. We recommend reviewing the privacy policy and terms & conditions of any site you visit, as Apellis Pharmaceuticals, Inc. is not responsible for their content.